Want to see CGTX full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.11Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlights significant progress in clinical efficacy signals and strategic cost management, extending the cash runway. However, challenges remain with increased net losses, NASDAQ compliance issues, and uncertain funding partnerships. The sentiment is balanced by advancements in manufacturing and patent filings.Company Guidance
Strong Efficacy Signals for Zervimesine
The company reported strong efficacy signals from two studies involving Alzheimer's disease and dementia with Lewy bodies (DLB), indicating potential value for patients and investors.
Cash Runway Extension
The strategic decision to conclude the Phase II dry AMD study is projected to result in cost savings that extend the company's cash runway into the fourth quarter of 2025.
Provisional Patent Applications Filed
Cognition Therapeutics has filed provisional patent applications for a novel chemical process developed for the manufacture of zervimesine, supporting future clinical studies and potential commercial manufacturing.
Progress in Manufacturing Capabilities
The company is working with a domestic contract manufacturing organization capable of producing commercial quantities of zervimesine, positioning them for potential future market demands.
CGTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CGTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $1.16 | $1.21 | +4.31% |
Mar 26, 2026 | $1.11 | $1.08 | -2.70% |
Nov 06, 2025 | $1.69 | $1.66 | -1.78% |
Aug 07, 2025 | $0.68 | $0.75 | +10.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cognition Therapeutics (CGTX) report earnings?
Cognition Therapeutics (CGTX) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
What is Cognition Therapeutics (CGTX) earnings time?
Cognition Therapeutics (CGTX) earnings time is at Aug 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CGTX EPS forecast?
CGTX EPS forecast for the fiscal quarter 2026 (Q2) is -0.06.